These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36312835)

  • 1. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.
    Macías-Rodríguez RU; Solís-Ortega AA; Ornelas-Arroyo VJ; Ruiz-Margáin A; González-Huezo MS; Urdiales-Morán NA; Román-Calleja BM; Mayorquín-Aguilar JM; González-Regueiro JA; Campos-Murguía A; Toledo-Coronado IV; Chapa-Ibargüengoitia M; Valencia-Peña B; Martínez-Cabrera CF; Flores-García NC
    World J Gastroenterol; 2022 Oct; 28(37):5444-5456. PubMed ID: 36312835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases.
    Fujii H; Fukumoto S; Enomoto M; Uchida-Kobayashi S; Kimura T; Tamori A; Nadatani Y; Takashima S; Nishimoto N; Kawada N
    Sci Rep; 2021 Jul; 11(1):13844. PubMed ID: 34226630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19.
    Campos-Murguía A; Román-Calleja BM; Toledo-Coronado IV; González-Regueiro JA; Solís-Ortega AA; Kúsulas-Delint D; Cruz-Contreras M; Cruz-Yedra N; Cubero FJ; Nevzorova YA; Martínez-Cabrera CF; Moreno-Guillén P; Lozano-Cruz OA; Chapa-Ibargüengoitia M; Gulías-Herrero A; Aguilar-Salinas CA; Ruiz-Margáin A; Macías-Rodríguez RU
    Dig Liver Dis; 2021 May; 53(5):525-533. PubMed ID: 33551355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.
    Vázquez-Medina MU; Cerda-Reyes E; Galeana-Pavón A; López-Luna CE; Ramírez-Portillo PM; Ibañez-Cervantes G; Torres-Vázquez J; Vargas-De-León C
    Hepatol Commun; 2022 Aug; 6(8):2000-2010. PubMed ID: 35438253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Hong JG; Yan LJ; Li X; Yao SY; Su P; Li HC; Ding ZN; Wang DX; Dong ZR; Li T
    World J Gastroenterol; 2022 Feb; 28(6):689-692. PubMed ID: 35317426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of TG/HDL-C Combined with Liver Function Indexes to Predict Metabolic-Associated Fatty Liver Disease].
    Xia JX; Zhao YH; He H; Liang SS; Gan W; Li GX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):764-769. PubMed ID: 36224676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
    Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and validation of a new nomogram to screen for MAFLD.
    Zou H; Zhao F; Lv X; Ma X; Xie Y
    Lipids Health Dis; 2022 Dec; 21(1):133. PubMed ID: 36482400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease.
    Michalak A; Guz M; Kozicka J; Cybulski M; Jeleniewicz W; Lach T; Cichoż-Lach H
    World J Gastroenterol; 2022 Oct; 28(38):5636-5647. PubMed ID: 36304090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults.
    Yang Z; Yu B; Wang Z; Li Z; Yang B; Zeng H; Yang S
    BMC Public Health; 2023 Mar; 23(1):584. PubMed ID: 36991357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care.
    Wang Z; Bertot LC; Jeffrey GP; Joseph J; Garas G; de Boer B; Huang Y; MacQuillan G; Wallace M; Smith B; Adams LA
    Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2041-2049.e5. PubMed ID: 34624564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of preoperative serum alanine aminotransferase and asparagine aminotransferase ratio on prognosis of patients with gastric cancer].
    Han BL; Wang YM; Xue YW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):65-70. PubMed ID: 31958933
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of liver function test- and inflammation-based prognostic scores for coronavirus disease 2019: a single center study.
    Cholongitas E; Bali T; Georgakopoulou VE; Kamiliou A; Vergos I; Makrodimitri S; Samara S; Triantafylou M; Basoulis D; Eliadi I; Karamanakos G; Sipsas NV; Samarkos M
    Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1165-1171. PubMed ID: 36170686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.
    Chen X; Goh GB; Huang J; Wu Y; Wang M; Kumar R; Lin S; Zhu Y
    J Clin Transl Hepatol; 2022 Aug; 10(4):589-594. PubMed ID: 36062270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.